Numerous genetic syndromes and inborn errors of metabolism exhibit distinctive cardiovascular malformations and conduction disturbances that manifest as classic electrocardiographic signatures.
1. Syndromic & Metabolic Electrocardiographic Matrix
| Syndrome / Disorder | Underlying Gene / Defect | Classical Cardiac Lesions | Electrocardiographic Signatures |
|---|---|---|---|
| Down Syndrome (Trisomy 21) | Trisomy 21 | Complete Atrioventricular Canal Defect (AVSD), VSD, ASD. | Left Superior Axis ($-30^\circ \text{ to } -90^\circ$), prolonged PR interval, counterclockwise frontal loop. |
| Turner Syndrome (45,X) | Monosomy X | Bicuspid Aortic Valve, Coarctation of Aorta, Hypoplastic Left Heart. | Severe LVH with strain, early repolarization abnormalities. |
| Noonan Syndrome | $PTPN11, SOS1, RAF1$ | Dysplastic Pulmonary Valve Stenosis, Hypertrophic Cardiomyopathy. | Extreme Right Axis or Northwest Axis, massive RVH, giant $Q$ waves in inferior leads. |
| Williams Syndrome | 7q11.23 microdeletion (Elastin) | Supravalvular Aortic Stenosis, Peripheral Pulmonary Stenosis. | Shortened $QTc$ (infantile hypercalcemia), severe biventricular hypertrophy, RVH. |
| Pompe Disease (GSD Type II) | Acid $\alpha$-glucosidase (GAA) | Massive generalized hypertrophic cardiomyopathy, heart failure. | Massive LVH Voltage ($R+S > 80-100\text{ mm}$) + Extremely Short PR Interval ($<0.08\text{ s}$) without true delta wave. |
| Danon Disease | $LAMP2$ (X-linked) | Severe hypertrophic cardiomyopathy, intellectual disability. | High-voltage LVH + Wolff-Parkinson-White Pre-excitation (frequent accessory pathways). |
| Friedreich Ataxia | Trinucleotide repeat (FXN) | Concentric hypertrophic cardiomyopathy. | Diffuse deep T-wave inversions across lateral/precordial leads, progressive LVH. |
| Holt-Oram Syndrome | $TBX5$ (Heart-Hand syndrome) | Secundum/Primum ASD, VSD, upper limb radial ray defects. | Progressive Atrioventricular Block (1st, 2nd, 3rd degree), junctional rhythms. |
2. Multimodality Diagnostic Investigations
- Enzyme Assay & Metabolic Panels: Dried blood spot acid $\alpha$-glucosidase activity for Pompe disease; serum calcium for Williams syndrome.
- Targeted Genetic Panels: Chromosomal microarray, Next-Generation Sequencing multigene panels.
- Echocardiography: Measures asymmetrical septal thickness Z-scores, outflow tract gradients, and biventricular dimensions.
3. Evidence-Based Clinical Management Protocols
- Enzyme Replacement Therapy (ERT): Recombinant human acid $\alpha$-glucosidase (Alglucosidase alfa / Avalglucosidase alfa) in infantile Pompe disease causes dramatic regression of cardiac hypertrophy and normalization of ECG voltages.
- Surveillance for Conduction System Degeneration: Lifelong annual Holter and ECG monitoring in Holt-Oram syndrome and Friedreich ataxia for prophylactic pacemaker planning.